Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Csl Ltd ADR (OP:CSLLY)

58.61 +0.31 (+0.54%)
Streaming Delayed Price Updated: 10:31 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Csl Ltd ADR

News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years. 
Via Investor's Business Daily
News headline image
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
News headline image
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines ↗
 
Via Benzinga
News headline image
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5... 
Via Benzinga
News headline image
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses ↗
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
News headline image
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia ↗
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program. 
Via Benzinga
News headline image
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space. 
Via Benzinga
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
5 Diverse Medical Stocks To Buy For 2023 And Beyond ↗
Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and... 
Via Talk Markets
News headline image
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗
 
Via Benzinga
News headline image
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗
 
Via Benzinga
News headline image
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults ↗
 
Via Benzinga
News headline image
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? ↗
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology. 
Via InvestorPlace
News headline image
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021 ↗
Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.